At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.7B, above the global median of $1.14B
- PositionGross margin is 77.6%, higher than 95% of its Medical Devices peers (median 56.6%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.70BUSDvs all stocks (USD)
Revenue (TTM)
699.19MUSDvs all stocks (USD)
Profit Margin
-21.25%vs Medical Devices peers
Beta
0.9880xvs all stocks
52-Week Change
8.46%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
1.70BUSDvs all stocks (USD)
Enterprise Value
1.50BUSDvs all stocks (USD)
Forward P/E
-18.21xvs Medical Devices peers
Price to Sales (TTM)
2.44xvs Medical Devices peers
Price to Book (MRQ)
5.06xvs Medical Devices peers
Enterprise to Revenue
2.15xvs Medical Devices peers
Enterprise to EBITDA
-11.01xvs Medical Devices peers
Gross Margin
77.61%vs Medical Devices peers
Profit Margin
-21.25%vs Medical Devices peers
Operating Margin
-5.75%vs Medical Devices peers
Return on Assets (TTM)
-9.26%vs Medical Devices peers
Return on Equity (TTM)
-43.22%vs Medical Devices peers
Revenue (TTM)
699.19MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.16USDUpdated Oct 28, 2026Quarterly Revenue Growth
15.60%vs Medical Devices peers
Gross Profit (TTM)
533.98MUSDvs all stocks (USD)
EBITDA (TTM)
-136.39MUSDvs all stocks (USD)
Net Income (TTM)
-148.56MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.60%vs Medical Devices peers
Operating Cash Flow (TTM)
-2.81MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
655.35MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
166.88MUSDFY2025 · Dec 31, 2025Gross Profit
488.47MUSDFY2025 · Dec 31, 2025Operating Income
-153.80MUSDvs all stocks (USD)
Pre-tax Income
-136.25MUSDFY2025 · Dec 31, 2025Income Tax Expense
-23.00KUSDFY2025 · Dec 31, 2025Net Income
-136.23MUSDFY2025 · Dec 31, 2025EBIT
-119.21MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-100.24MUSDFY2025 · Dec 31, 2025Research & Development
224.54MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
417.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.87MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
17.04MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.22USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.22USDFY2025 · Dec 31, 2025Basic Shares Outstanding
111.47MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
111.47MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-136.23MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.83MUSDFY2025 · Dec 31, 2025Free Cash Flow
-77.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
103.39MUSDFY2025 · Dec 31, 2025Income Tax Paid
30.67MUSDFY2025 · Dec 31, 2025Interest Paid
13.41MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-136.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.65MUSDFY2025 · Dec 31, 2025Stock-based Compensation
104.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.95MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-38.94MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-95.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-26.65MUSDFY2025 · Dec 31, 2025Purchase of Investments
-821.08MUSDFY2025 · Dec 31, 2025Sale of Investments
1.28BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
437.28MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
99.98MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-560.95MUSDFY2025 · Dec 31, 2025Other Financing Charges
-146.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-457.46MUSDFY2025 · Dec 31, 2025Shares Outstanding
116.44MSharesUpdated Oct 28, 2026Float Shares
96.42MSharesUpdated Oct 28, 2026Shares Short
11.16MSharesUpdated Oct 28, 2026Short Ratio
10.35daysvs all stocks
Short % of Shares Outstanding
12.96%vs all stocks
% Held by Insiders
9.96%vs all stocks
% Held by Institutions
90.79%vs all stocks
Total Cash (MRQ)
440.56MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.78USDUpdated Oct 28, 2026Total Debt (MRQ)
233.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6904xvs Medical Devices peers
Current Ratio (MRQ)
2.89xvs Medical Devices peers
Book Value per Share (MRQ)
2.90USDUpdated Oct 28, 2026Total Assets
804.33MUSDvs all stocks (USD)
Total Current Assets
646.73MUSDFY2025 · Dec 31, 2025Total Liabilities
463.86MUSDFY2025 · Dec 31, 2025Total Non-current Assets
157.59MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
240.63MUSDFY2025 · Dec 31, 2025Total Current Liabilities
223.23MUSDFY2025 · Dec 31, 2025Cash
7.40MUSDFY2025 · Dec 31, 2025Cash Equivalents
86.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.55MUSDFY2025 · Dec 31, 2025Other Short-term Investments
354.13MUSDFY2025 · Dec 31, 2025Accounts Receivable
89.44MUSDFY2025 · Dec 31, 2025Inventory
41.11MUSDFY2025 · Dec 31, 2025Accounts Payable
122.23MUSDFY2025 · Dec 31, 2025Short-term Debt
11.66MUSDFY2025 · Dec 31, 2025Deferred Revenue
15.95MUSDFY2025 · Dec 31, 2025Long-term Debt
236.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-1.29BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
340.47MUSDvs all stocks (USD)
52-Week Low
9.82USDUpdated Oct 28, 202652-Week High
21.45USDUpdated Oct 28, 202652-Week Change
8.46%vs all stocks
Beta
0.9880xvs all stocks
50-Day MA
16.15USDUpdated Oct 28, 2026200-Day MA
14.82USDUpdated Oct 28, 2026Avg 10-Day Volume
1.46MSharesUpdated Oct 28, 2026Avg 30-Day Volume
1.43MSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-1.30USDUpdated Oct 28, 2026Other Income / Expense
-4.32MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 77.6%, higher than 95% of its Medical Devices peers (median 56.6%)Significant
Gross margin: 0.78Industry median: 0.57Industry P95: 0.74Peers compared: 54.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: -0.21
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.89Altman Z-Score: 0.91
Financial Health
Altman Z-Score 0.91: distress zoneCritical
Altman Z-Score: 0.91
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.7B, above the global median of $1.14BNotable
Market cap (USD): 1,702,438,180Global Median: 1,137,180,293.291
Revenue is $699.19M, above the global median of $566.17MNotable
Revenue (USD): 699,193,024Global Median: 566,172,992
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Acro Biosystems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow